AKUS Akouos, Inc.

Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing loss. Leveraging its precision genetic medicine platform that incorporates a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. The Company’s lead product candidate, AK-OTOF, is a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene.

$7.81
As of 12/03/2021     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/26/2020
Outstanding shares:  34,493,896
Average volume:  146,464
Market cap:   $304,926,041
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    00973J101
ISIN:        US00973J1016
Sedol:      BKPVFN5

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   1.05
PS ratio:   0.00
Return on equity:   -28.99%
Net income %:   0.00%